Clinical Trial Update: Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 study of ocular sirolimus in combination with Lucentis for age-related macular degeneration was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Santen Inc. | Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 2 | Status: TERMINATED